• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    2/14/23 5:00:28 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DYAI alert in real time by email
    SC 13G/A 1 emalf20230212_sc13ga.htm SCHEDULE 13G/A emalf20230212_sc13ga.htm
     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    ____________________________________________

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

    DYADIC INTERNATIONAL, INC.


    (Name of Issuer)

     

    Common Stock, $0.001 par value


    (Title of Class of Securities)

     

    26745T101


    (CUSIP Number)

     

    December 31, 2022


    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Page 1 of 6

     

     

    CUSIP No. 26745T101

    (1)

    NAMES OF REPORTING PERSONS

    Mark A. Emalfarb

    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a) ☐
    (b) ☐

    (3)

    SEC USE ONLY

     

    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    Number of
    Shares

    (5)

    SOLE VOTING POWER

    5,207,493 (1)

    Beneficially

    Owned

    (6)

    SHARED VOTING POWER

    0

    by Each
    Reporting

    (7)

    SOLE DISPOSITIVE POWER

    5,207,493 (1)

    Person With:

    (8)

    SHARED DISPOSITIVE POWER

    0

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,207,493(1)

    (10)

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐

    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    17.7%

    (12)

    TYPE OF REPORTING PERSON

    IN

     

    (1) See Item 4 herein.

     

    Page 2 of 6

     

     

     

    Item 1

    (a)

    Name of issuer:

         
       

    Dyadic International, Inc.

         

     

    (b)

    Address of issuer’s principal executive offices:

         
       

    140 Intracoastal Pointe Drive

       

    Suite 404

       

    Jupiter, Florida 33477

         

    Item 2

    (a)

    Name of person filing:

         
       

    Mark A. Emalfarb

         

     

    (b)

    Address or principal business office or, if none, residence:

         
       

    140 Intracoastal Pointe Drive

       

    Suite 404

       

    Jupiter, Florida 33477

         

     

    (c)

    Citizenship:

         
       

    United States of America

         

     

    (d)

    Title of class of securities:

         
       

    Common Stock, $0.001 par value

         

     

    (e)

    CUSIP No.:

         
       

    26745T101

     

    Page 3 of 6

     

     

     

    Item 3

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

       

     

    (a)

    ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

         

     

    (b)

    ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

         

     

    (c)

    ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

         

     

    (d)

    ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

         

     

    (e)

    ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

         

     

    (f)

    ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

         

     

    (g)

    ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

         

     

    (h)

    ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

         

     

    (i)

    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

         

     

    (j)

    ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

         

     

    (k)

    ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

       
        Not applicable.
         

    Item 4

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

         

     

    (a)

    Amount beneficially owned:

         
        5,207,493
         

     

    (b)

    Percent of class:

         
       

    17.7%

     

    Page 4 of 6

     

     

     

     

    (c)

    Number of shares as to which the person has:

         
       

    (i)

    Sole power to vote or direct the vote

           
         

    5,207,493 (1)

           
       

    (ii)

    Shared power to vote or direct the vote

           
         

    0

           
       

    (iii)

    Sole power to dispose or to direct the disposition of

           
         

    5,207,493 (1)

           
        (iv)

    Shared power to dispose or to direct the disposition of

           
       

     

    0
           
      (1) The reporting person beneficially owns 5,207,493 shares through the Mark A. Emalfarb Trust U/A/D October 1, 1987, of which the reporting person is the sole beneficiary and serves as sole trustee. Includes 675,000 shares issuable upon the exercise of options presently exercisable.

     

    Item 5

    Ownership of 5 Percent or Less of a Class.

     

    Not applicable.

     

    Item 6

    Ownership of More than 5 Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9

    Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10

    Certifications.

     

    Not applicable.

     

    Page 5 of 6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

      /s /  Mark A. Emalfarb         
             Mark A. Emalfarb

     

    Page 6 of 6
    Get the next $DYAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DYAI

    DatePrice TargetRatingAnalyst
    7/18/2022Buy → Neutral
    Dawson James
    12/17/2021$7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DYAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

      JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560

      5/1/25 3:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic to Present at World Vaccine Congress | Washington

      JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C. World Vaccine Congress | Washington, D.C.April 22–24, 2025Presentation: Wednesday, April 23, 2025 | 12:40

      4/16/25 2:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Reports 2024 Year-End Financial Results and Business Updates

      Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applicationsContinued advancements in animal and human healthCash and investment-grade securities of $9.3 million as of December 31, 20

      3/26/25 4:05:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kaye Jack exercised 30,000 shares at a strike of $1.33 and covered exercise/tax liability with 27,517 shares, increasing direct ownership by 4% to 59,649 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      3/7/25 4:07:16 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Herbst Seth exercised 25,000 shares at a strike of $0.97, increasing direct ownership by 16% to 180,759 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      1/8/25 5:19:28 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kaye Jack converted options into 23,585 shares, increasing direct ownership by 70% to 57,166 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      1/7/25 6:08:20 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      2/13/24 4:41:59 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      2/1/24 4:15:18 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      3/14/23 4:01:06 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Leadership Updates

    Live Leadership Updates

    See more
    • Dyadic Appoints Doug Pace to Its Executive Leadership Team

      JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and

      10/9/23 8:30:00 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Appoints Chief Business Officer to Executive Leadership Team

      JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products today announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this role supports the global commercialization of the Company's new and existing business initiatives, including corporate strategy, business and corporate develo

      11/9/21 8:30:00 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Financials

    Live finance-specific insights

    See more
    • Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

      JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560

      5/1/25 3:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Reports 2024 Year-End Financial Results and Business Updates

      Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applicationsContinued advancements in animal and human healthCash and investment-grade securities of $9.3 million as of December 31, 20

      3/26/25 4:05:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025

      JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the year ended 2024 and host a corporate update conference call on Wednesday, March 26, 2025. Conference Call Information Date: Wednesday, March 26, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-85

      3/12/25 4:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dyadic International downgraded by Dawson James

      Dawson James downgraded Dyadic International from Buy to Neutral

      7/18/22 9:59:51 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Dyadic International with a new price target

      HC Wainwright & Co. initiated coverage of Dyadic International with a rating of Buy and set a new price target of $7.00

      12/17/21 6:17:22 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    SEC Filings

    See more
    • Dyadic International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      5/5/25 5:03:31 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Dyadic International Inc.

      DEFA14A - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      4/29/25 4:33:14 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Dyadic International Inc.

      DEF 14A - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      4/29/25 4:32:22 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care